A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers.

ABSTRACT:

Objective

Obicetrapib, a selective cholesteryl ester transfer protein inhibitor in development for the treatment of dyslipidemia and cardiovascular risk, is expected to be administered with high-intensity statins in clinical practice. This study was performed to assess the effect of obicetrapib on the pharmacokinetics (PK) of atorvastatin and rosuvastatin.

Methods

An open-label study was conducted to evaluate the PK of atorvastatin 80 mg (cohort 1, n = 42) or rosuvastatin 40 mg (cohort 2, n = 32, non-Asians) with and without co-administration of 10 mg obicetrapib in healthy adult males and females. Study participants received statin on day - 4, obicetrapib on days 1-11, statin co-administered with obicetrapib on day 12, and obicetrapib on days 13-17. Blood samples were colle

SUBMITTER: Kastelein JJP 

PROVIDER: S-EPMC12378308 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature